Current News

Walbrook PR appointed by One Health Group PLC

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR & Investor Relations advisor to AIM quoted One Health Group plc (AIM: OHGR), an independent provider of NHS-funded medical procedures.

20 June 2025 • Read more

Walbrook PR - Amcomri Group plc

Walbrook PR, which provides high quality Financial PR and Investor Relations services to Small Cap and AIM listed companies, is pleased to have supported Amcomri Group plc (AIM: AMCO), the "Buy, Improve, Build" UK focused specialist engineering services and industrial manufacturing group, on its successful £12m placing and admission to the AIM market by way of an IPO.

20 December 2024 • Read more

Walbrook PR – eXymes

Walbrook PR, which provides high quality Financial PR, Corporate Communications and Investor Relations to Small Cap and AIM listed companies, announces it is acting as strategic communications advisor for eXymes, a high growth genomics company, with a disruptive DNA/RNA extraction technology.

01 June 2024 • Read more

Walbrook PR – MediaZest

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it is acting for MediaZest (AIM: MDZ) (the “Group”), a creative audio-visual solutions provider that specialises in delivering innovative digital signage and audio systems to leading retailers, brand owners and corporations.

01 February 2024 • Read more

Walbrook PR – ILC Therapeutics

Walbrook PR, which provides high quality Strategic communications and Investor Relations support to Small and AIM listed companies, announces it is acting as corporate communications advisor for ILC Therapeutics, a Scottish based biotechnology company developing an exciting novel drug class.

01 August 2023 • Read more

Walbrook PR – SigmaRoc Plc

Walbrook PR, which provides high quality Financial PR and Investor Relations services to Small Cap and AIM listed companies, announces that it is acting as Financial PR & Investor Relations advisor for SigmaRoc plc (AIM: SRC), the specialist quarrying group that invests, improves, integrates and innovates companies within the industrial materials space, in both the UK and Europe.

17 July 2023 • Read more

Walbrook PR - Inspiration Healthcare

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it is acting as Financial PR & Investor Relations advisor for Inspiration Healthcare Group plc (AIM: IHC), a leading developer and manufacturer, with a focus on pioneering best-in-class, specialist neonatal intensive care medical devices.

12 April 2023 • Read more

Walbrook PR – Novacyt Group

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it is acting as Financial PR & Investor Relations advisor for Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests.

12 April 2023 • Read more

Walbrook PR - Victoria Plc

12 April 2023 • Read more

Anna Dunphy, Lianne Applegarth and Nick Rome

Huge congratulations to Anna Dunphy, Lianne Applegarth and Nick Rome on their recent promotions to Director.

12 April 2023 • Read more

Alice Woodings

Huge congratulations to Alice Woodings on her promotion to Associate Director.

12 April 2023 • Read more

Walbrook PR - Zamaz plc

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it is acting as Financial PR & Investor Relations advisor for Zamaz plc (LSE:ZAMZ), the on-line consumer goods business that originates, acquires or licenses, operates and scales small and medium-sized brands with category-winning products on global marketplaces; with a focus on ecologically produced, ethically, and health supportive brands and products. Walbrook is managing the Company’s ongoing communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

20 September 2022 • Read more

Louis Ashe-Jepson

Congratulations to Louis Ashe-Jepson on his recent promotion to Senior Associate

04 July 2022 • Read more

Walbrook PR - Spectral MD

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, congratulates its client Spectral MD Holdings, Ltd. (AIM: SMD) on their win of the Best Technology Award at the European Mediscience Awards 2022 on 16 June 2022.

04 July 2022 • Read more

Walbrook PR AQSE IPO – ProBiotix Health PLC

Walbrook PR, one of the UK’s leading providers of Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it has acted as Financial PR & Investor Relations advisor for the Aquis Stock Exchange (“AQSE”) IPO of ProBiotix Health plc (“ProBiotix”), the life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions. ProBiotix was established by AIM-listed OptiBiotix Health plc to develop next-generation microbiome solutions for a wide range of health conditions and to deliver commercially successful products supported by a strong scientific evidence base.

31 March 2022 • Read more

Walbrook PR Welcomes Light Science Technologies Holdings to AIM

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it is acting as Financial PR & Investor Relations advisor for Light Science Technologies Holdings plc (AIM: “LST”), the controlled environment agriculture (“CEA”) technology and contract electronics manufacturing (“CEM”) Group. Having advised the Company ahead of its successful IPO on AIM last month, Walbrook is now managing the Company’s ongoing communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

16 November 2021 • Read more

Walbrook PR closes in on pole position in AIM adviser rankings

Walbrook PR, one of the UK’s leading providers of Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its rise to second place in the AIM adviser rankings by most financial PR clients listed on the London Stock Exchange’s AIM market, according to the latest quarterly report from Adviser Rankings.

01 November 2021 • Read more

Walbrook PR Appointed by Pittards plc

Walbrook PR, one of the UK’s leading providers of Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as PR & IR advisor to Pittards plc (“Pittards”), the specialist producer of technically advanced leather and luxury leather goods for retailers, manufacturers and distributors. The team at Walbrook will manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

01 September 2021 • Read more

WALBROOK PR Appointed By Abingdon Health plc

Walbrook PR, one of the UK’s leading providers of Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as PR & IR advisor to Abingdon Health plc (“Abingdon”), a leading international developer and manufacturer of high quality and effective rapid tests. The team at Walbrook will manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

09 August 2021 • Read more

Walbrook PR Welcomes GENinCode to AIM

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it has acted as Financial PR & Investor Relations advisor for the AIM IPO of GENinCode plc (AIM: “GENI”), the cardiovascular disease ("CVD") company focused on predictive genetics for the prevention of cardiovascular disease. The team at Walbrook will now manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

22 July 2021 • Read more